Loading…
Cellectar Biosciences, Inc. is projected to rise to $3.94 by 2027, a +25% move from its current price of $3.14. CLRB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.03 | $3.14 | $3.26 | +0.05% |
| May 30 | $2.98 | $3.14 | $3.31 | +0.09% |
| May 31 | $2.95 | $3.14 | $3.35 | +0.14% |
| Jun 1 | $2.92 | $3.15 | $3.38 | +0.18% |
| Jun 2 | $2.90 | $3.15 | $3.41 | +0.23% |
| Jun 3 | $2.88 | $3.15 | $3.44 | +0.27% |
| Jun 4 | $2.86 | $3.15 | $3.47 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.86 | $3.15 | $3.47 | +0.32% |
| Week 2 | $2.76 | $3.16 | $3.62 | +0.63% |
| Week 3 | $2.68 | $3.17 | $3.75 | +0.95% |
| Week 4 | $2.62 | $3.18 | $3.86 | +1.27% |
| Week 5 | $2.57 | $3.19 | $3.96 | +1.59% |
| Week 6 | $2.53 | $3.20 | $4.05 | +1.91% |
| Week 7 | $2.49 | $3.21 | $4.14 | +2.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellectar Biosciences, Inc. is a clinical biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for relapsed or refractory (r/r) Waldenström's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborations with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB is the publicly traded stock of Cellectar Biosciences, Inc. The current price is $3.20 per share, and the market cap is $25.57M, with a market-rank of 4875.
The forecast landscape shows an upward price trajectory over the coming years, with the average price rising from the current level toward higher targets and notable upside by 2040 and 2050. Specific forecasted averages include 2026 at $3.20, 2027 at $4.01, 2028 at $4.26, 2029 at $4.45, 2030 at $4.48, 2031 at $4.25, 2032 at $4.11, 2033 at $4.46, 2034 at $5.82, 2035 at $6.14, 2040 at $7.33, and 2050 at $12.04, with corresponding max values up to $25.59 by 2050.
A major floor 32.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.5% below — buyers have tended to step in here.
The nearest ceiling, 12.4% above — a clean break opens room to run.
A major ceiling 28.9% above — clearing it would confirm fresh momentum.
Key CLRB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLRB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.16 | Sell | $3.14 | Buy |
| MA 10 | $3.12 | Buy | $3.12 | Buy |
| MA 20 | $3.05 | Buy | $3.06 | Buy |
| MA 50 | $2.93 | Buy | $3.02 | Buy |
| MA 100 | $3.11 | Buy | $3.23 | Sell |
| MA 200 | $3.63 | Sell | $5.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.14 | Neutral |
| Stoch RSI (14) | 36.15 | Neutral |
| CCI (20) | 34.59 | Neutral |
| Williams %R (14) | -42.11 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 1.29 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 57.89 | Neutral |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | 0.20 | Buy |
| Ultimate (7,14,28) | 49.85 | Neutral |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 3.16 | Sell |
| ADX (14) | 11.79 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture points to a bullish tilt with RSI(14) at 60 and trends above key moving averages. The SMA50 is $2.94 and the SMA200 is $3.65, placing current price dynamics near the middle of a rising drift.
Support sits at $2.56 and resistance at $3.53, framing a modest near-term band. Over the last 30 days, the price ranged from $2.49 to $4.12, indicating active volatility within a bullish context.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.50 | $3.14 | $4.18 | 0% | Neutral | |
| $3.02 | $3.94 | $5.50 | +25% | Bullish | |
| $3.13 | $4.23 | $6.18 | +35% | Bullish | |
| $3.15 | $4.39 | $6.65 | +40% | Bullish | |
| $3.06 | $4.40 | $6.86 | +40% | Bullish | |
| $2.90 | $4.29 | $6.86 | +37% | Bullish | |
| $2.74 | $4.15 | $6.79 | +32% | Bullish | |
| $2.89 | $4.47 | $7.48 | +42% | Bullish | |
| $3.72 | $5.88 | $10.03 | +87% | Bullish | |
| $3.80 | $6.16 | $10.69 | +96% | Bullish | |
| $4.21 | $7.53 | $14.08 | +140% | Bullish | |
| $5.72 | $12.26 | $25.54 | +291% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.50 | $3.14 | $3.70 | +0.00% |
| June 2026 | $2.72 | $3.22 | $3.91 | +2.49% |
| July 2026 | $2.73 | $3.27 | $4.05 | +1.66% |
| August 2026 | $2.59 | $3.13 | $3.93 | -4.38% |
| September 2026 | $2.56 | $3.11 | $3.95 | -0.61% |
| October 2026 | $2.68 | $3.28 | $4.21 | +5.57% |
| November 2026 | $2.68 | $3.30 | $4.27 | +0.65% |
| December 2026 | $2.59 | $3.21 | $4.18 | -2.98% |
Click any year to see its month-by-month CLRB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cellectar Biosciences, Inc.'s 2026 outlook centres on $3.14, within a $2.50 to $4.18 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CLRB could reach as high as $5.50, with a base case around $3.94 and support toward $3.02 — roughly +25% from $3.14. Buyers look set to stay in control over this stretch.
Expect CLRB to range from $3.13 to $6.18 through 2028. The $4.23 average target implies a +35% move from current prices. That is up +7% on the projected 2027 average. Momentum favours further upside here.
The CLRB price prediction for 2029 points to an average of $4.39 (low $3.15, high $6.65) — a potential gain of +40% on today's $3.14. Buyers look set to stay in control over this stretch.
In 2030, CLRB is projected to trade between $3.06 and $6.86, averaging $4.40 — a potential gain of +40% from today's $3.14. That is up 0% on the projected 2029 average. Momentum favours further upside here.
Cellectar Biosciences, Inc.'s 2031 outlook centres on $4.29, within a $2.90 to $6.86 range. That is -3% versus the projected 2030 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CLRB could reach as high as $6.79, with a base case around $4.15 and support toward $2.74 — roughly +32% from $3.14. Momentum favours further upside here.
Expect CLRB to range from $2.89 to $7.48 through 2033. The $4.47 average target implies a +42% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CLRB price prediction for 2034 points to an average of $5.88 (low $3.72, high $10.03) — a potential gain of +87% on today's $3.14. Momentum favours further upside here.
In 2035, CLRB is projected to trade between $3.80 and $10.69, averaging $6.16 — a potential gain of +96% from today's $3.14. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cellectar Biosciences, Inc.'s 2040 outlook centres on $7.53, within a $4.21 to $14.08 range. That is up +22% on the projected 2035 average. That marks a +140% change versus current levels. Momentum favours further upside here.
By 2050, CLRB could reach as high as $25.54, with a base case around $12.26 and support toward $5.72 — roughly +291% from $3.14. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLRB today (≈ 318.471338 CLRB) could be worth
$3,905.28
+$2,905.28 (+291%) by 2050 · US Dollar
Based on the average projected CLRB price of $12.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLRBwould be worth at today's price.
$1,000 invested in CLRB on May 27, 2025 (≈ 133.333333 CLRB) would be worth
$418.67
-$581.33 (-58.1%) today · 0.42× · US Dollar
Based on a CLRB entry price of $7.5 vs. today's $3.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.17 | $990.54 | -0.9% |
| 1 month ago | $2.61 | $1,203.07 | +20.3% |
| 3 months ago | $3.51 | $894.59 | -10.5% |
| 6 months ago | $3.59 | $874.65 | -12.5% |
| 1 year ago | $7.5 | $418.67 | -58.1% |
| All time (5.0y) ago | $486 | $6.46 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLRB forecast.
Our base-case forecast reaches $6.30 around 2040.
Implied market cap at $6.30: $50.35M
The multi-year outlook shows a bullish trajectory with meaningful upside through 2030 and beyond. The 2030 average price is $4.48 with a 40.1% ROI, followed by continued gains through 2040 (average $7.33, ROI 129.1%) and 2050 (average $12.04, ROI 276.1%). Earlier years deliver steady gains too, such as 2027 average $4.01 (ROI 25.4%), 2028 average $4.26 (ROI 33.1%), and 2029 average $4.45 (ROI 39.1%).
Max forecasts extend to $10.83 by 2035 and reach $13.96 in 2040, with a long-run upside cap near $25.59 in 2050.
The sentiment is bullish across the forecast horizon, and the model underscores upside potential alongside higher volatility. As with all forecasts, these are estimates, not guarantees. Investors should consider the inherent uncertainty and the small-cap nature of the asset when evaluating long-term exposure.
Tap a question to reveal the answer.
The forecast shows an average price of $4.48 in 2030 with a potential ROI of 40.1%.
Forecasts show bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $4.01; 2028 avg $4.26; 2029 avg $4.45; 2030 avg $4.48) and upside in 2040 ($7.33 avg) and 2050 ($12.04 avg). These are estimates, not guarantees.
Yes. The max forecasts include $10.08 in 2034 and $10.83 in 2035, with higher maxima of $13.96 in 2040 and $25.59 in 2050.
Current price is $3.20 and market cap is $25.57M.
The 30-day range is from $2.49 to $4.12.
Cellectar Biosciences, Inc. Community Discussion
0Share your Cellectar Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.